Summary
For Year 2026-27, Glenmark Pharmaceuticals reports the following shareholding: Total Promoters at 46.65%, Mutual Fund at 16.8%, Insurance at 1%, Foreign Institutional Investors at 20.35%, Domestic Institutional Investors at 1.52%, and Retail at 13.68%. This breakdown provides a quick snapshot of ownership distribution for Glenmark Pharmaceuticals in 2026-27.
Glenmark Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Glenmark Pharmaceuticals stands at 46.65% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Glenmark Pharmaceuticals is 20.35% and 1.52% respectively.
The retail shareholding of the Glenmark Pharmaceuticals is 13.68%.
Changes in shareholding patterns of Glenmark Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Glenmark Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Glenmark Pharmaceuticals Associated Pages
- Glenmark Pharmaceuticals Share Price
- Glenmark Pharmaceuticals Share Price chart
- Glenmark Pharmaceuticals Fundamental Analysis
- Glenmark Pharmaceuticals Technical Analysis
- Glenmark Pharmaceuticals Peer Comparison
- Glenmark Pharmaceuticals Share Price History
- Glenmark Pharmaceuticals Dividend
- Glenmark Pharmaceuticals Board of Directors
